<p>A fast-dissolving vaginal insert that women would use at or around the time of sex as an “on-demand” HIV prevention method is being evaluated in a new early phase study being conducted by <a href="https://www.matrix4prevention.org/">MATRIX</a>, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women. The MATRIX study is only the second Phase 1 trial of the <a href="https://www.matrix4prevention.org/products/tafevg-fast-dissolving-vaginal-insert">fast-dissolving insert</a> used vaginally and the first to evaluate its use in African women. The insert, which contains the antiretroviral (ARV) drugs tenofovir alafenamide (TAF) and elvitegravir (EVG), is the only on-demand HIV prevention product for use by women currently being evaluated in clinical trials.</p>
A fast-dissolving vaginal insert that women would use at or around the time of sex as an "on-demand" HIV prevention method is being evaluated in a new early phase study being conducted by MATRIX, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women.
A vaginal film designed to slowly dissolve over the course of 30 days is being put to the test for the first time in a study launched this week that aims to determine its feasibility and acceptability as a potential HIV prevention method for women.